Pages that link to "Q39799354"
Jump to navigation
Jump to search
The following pages link to GHRH antagonist causes DNA damage leading to p21 mediated cell cycle arrest and apoptosis in human colon cancer cells (Q39799354):
Displaying 26 items.
- Integrative Pathway Analysis Using Graph-Based Learning with Applications to TCGA Colon and Ovarian Data (Q30842944) (← links)
- Growth hormone-releasing hormone: not only a neurohormone. (Q34181179) (← links)
- Mechanisms of synergism between antagonists of growth hormone-releasing hormone and antagonists of luteinizing hormone-releasing hormone in shrinking experimental benign prostatic hyperplasia (Q34529072) (← links)
- Antagonists of growth hormone-releasing hormone (GHRH) reduce prostate size in experimental benign prostatic hyperplasia (Q34621536) (← links)
- Antagonistic analogs of growth hormone-releasing hormone increase the efficacy of treatment of triple negative breast cancer in nude mice with doxorubicin; A preclinical study (Q34781112) (← links)
- Potentiating effects of GHRH analogs on the response to chemotherapy (Q35565027) (← links)
- Cooperative effects of Akt-1 and Raf-1 on the induction of cellular senescence in doxorubicin or tamoxifen treated breast cancer cells (Q35640301) (← links)
- Recent progress in targeting cancer (Q35740782) (← links)
- Antagonists of growth hormone-releasing hormone inhibit growth of androgen-independent prostate cancer through inactivation of ERK and Akt kinases (Q35749794) (← links)
- Chemoprevention of familial adenomatous polyposis by bromo-noscapine (EM011) in the Apc(Min/+) mouse model (Q35996030) (← links)
- Combination of gastrin-releasing peptide antagonist with cytotoxic agents produces synergistic inhibition of growth of human experimental colon cancers (Q36116233) (← links)
- Novel GHRH antagonists suppress the growth of human malignant melanoma by restoring nuclear p27 function. (Q36189529) (← links)
- Short-term, supra-physiological rhGH administration induces transient DNA damage in peripheral lymphocytes of healthy women. (Q36283802) (← links)
- GHRH antagonist when combined with cytotoxic agents induces S-phase arrest and additive growth inhibition of human colon cancer (Q36472257) (← links)
- Cancer treatment using peptides: current therapies and future prospects (Q36515785) (← links)
- Antagonists of growth hormone-releasing hormone suppress in vivo tumor growth and gene expression in triple negative breast cancers (Q36862773) (← links)
- Growth hormone-releasing hormone receptor antagonists inhibit human gastric cancer through downregulation of PAK1-STAT3/NF-κB signaling (Q37534187) (← links)
- Targeted therapy in advanced metastatic colorectal cancer: current concepts and perspectives (Q38216009) (← links)
- Lentivirus-mediated siRNA interference targeting SGO-1 inhibits human NSCLC cell growth (Q39429560) (← links)
- A correlation of endocrine and anticancer effects of some antagonists of GHRH. (Q39679789) (← links)
- Anti-proliferative and pro-apoptotic effects of GHRH antagonists in prostate cancer (Q42330184) (← links)
- Synthesis and structure-activity studies on novel analogs of human growth hormone releasing hormone (GHRH) with enhanced inhibitory activities on tumor growth (Q47983429) (← links)
- Inhibition of Experimental Small Cell and Non-Small Cell Lung Cancers by Novel Antagonists of Growth Hormone- Releasing Hormone. (Q50050314) (← links)
- Growth hormone-releasing hormone receptor antagonists modify molecular machinery in the progression of prostate cancer (Q57165992) (← links)
- Antagonists of growth hormone-releasing hormone (GHRH) inhibit the growth of human malignant pleural mesothelioma (Q61813762) (← links)
- Possible predictors of histopathological response to neoadjuvant chemoradiotherapy for rectal cancer (Q82905931) (← links)